Tempus AI’s stock has surged 82.4% year-over-year as the company reports a 47% increase in Genomics revenues and a 62% expansion in its Data & Services segment during the most recent fiscal year. The firm achieved four new FDA clearances for its liquid biopsy assays, supporting broader clinical adoption. Additionally, Tempus AI posted its first positive adjusted EBITDA quarter, driven by operating leverage in its laboratory network and a 25% reduction in cost of goods sold per test. Management highlighted that new enterprise agreements with three of the top five global biopharma companies are expected to contribute an incremental $50 million in annual recurring revenue beginning next quarter.

Tempus AI announced the acceptance of eight abstracts for presentation at the 2026 ASCO® Gastrointestinal Cancers Symposium, taking place January 8–10 in San Francisco. The research portfolio includes clinical validation data on a novel AI-powered biomarker panel for colorectal cancer, which demonstrated 94% sensitivity and 88% specificity in a 1,200-patient multicenter study. Additional posters will cover real-world evidence analyses of therapy sequencing in pancreatic cancer and novel applications of machine learning to predict immunotherapy response. These presentations underscore Tempus AI’s strategic focus on gastrointestinal oncology and its commitment to translating large-scale multi-omic datasets into actionable clinical insights.